{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:49:56Z","timestamp":1747151396155,"version":"3.40.5"},"reference-count":10,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Immediate\u2010release forms of generic mixed amphetamine salts (MAS) have been the subject of passive surveillance reports signaling lack of effectiveness. We examined switching patterns that might suggest whether long\u2010term users of specific MAS are more likely to switch away or switch back after use of the MAS of interest in the FDA's Sentinel Distributed Database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We required at least 60\u2010day continuous supply of selected MAS grouped by Abbreviated New Drug Application (ANDA) to describe patterns of switching away from and to generics approved under the ANDAs of interest among individuals ages 15\u201364\u2009years with attention deficit hyperactivity disorder or narcolepsy during 2013\u20132019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed the greatest number of treatment episodes for ANDA 040422 (<jats:italic>n<\/jats:italic>\u2009=\u2009525\u2009771), followed by ANDA 202424 (<jats:italic>n<\/jats:italic>\u2009=\u2009181\u2009693), ANDA 040439 (<jats:italic>n<\/jats:italic>\u2009=\u200962\u2009363), ANDA 040440 (<jats:italic>n<\/jats:italic>\u2009=\u200921\u2009143), and ANDA 040480 (<jats:italic>n<\/jats:italic>\u2009=\u20098792). Of those with switches away from their original ANDA, episodes initiated on generic products under ANDA 040422 (48.6%) and ANDA 202424 (43.0%) were most likely to switch back, while those initiated on generic product under ANDA 040480 were least likely (24.1%). Of those episodes with switches to a generic under an ANDA of interest, about one\u2010third (range 27.1% to 37.0%) switched back to the same product. These switches back had a median time to switch of about 30\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These descriptive analyses, although subject to limitations, did not suggest increased switching away or switching back after use of the generics of interest. Continued post\u2010marketing surveillance is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5661","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:13:34Z","timestamp":1687623214000},"page":"1178-1183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching patterns of immediate\u2010release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15\u201364\u2009years in the United States, 2013\u20132019"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-1502","authenticated-orcid":false,"given":"Silvia","family":"Perez\u2010Vilar","sequence":"first","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Kempner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-2890","authenticated-orcid":false,"given":"Sarah K.","family":"Dutcher","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-4704","authenticated-orcid":false,"given":"Talia J.","family":"Menzin","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-3881","authenticated-orcid":false,"given":"Corinne","family":"Woods","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-2477","authenticated-orcid":false,"given":"Kira","family":"Leishear","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Osterhout","sequence":"additional","affiliation":[{"name":"Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-3902","authenticated-orcid":false,"given":"Sruthi","family":"Adimadhyam","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-0489","authenticated-orcid":false,"given":"Modupeola","family":"Adereti","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Carruth","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Hansbury","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhminder K.","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-0298","authenticated-orcid":false,"given":"Jennifer G.","family":"Lyons","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"US Food and Drug Administration.Adderall Teva Branded Pharmaceutical Products R&D Inc. US labeling.2022."},{"key":"e_1_2_10_3_1","unstructured":"US Food and Drug Administration.Referencing approved drug products in ANDA submissions guidance for industry. Accessed April 18.2020https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/referencing\u2010approved\u2010drug\u2010products\u2010anda\u2010submissions\u2010guidance\u2010industry"},{"key":"e_1_2_10_4_1","unstructured":"US Food and Drug Administration.Abbreviated new drug application (ANDA): 040422. DEXTROAMP SACCHARATE AMP ASPARTATE DEXTROAMP SULFATE AND AMP SULFATE. Original approval. Accessed May 27.2002https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/040422.PDF"},{"key":"e_1_2_10_5_1","unstructured":"US Food and Drug Administration.MedWatch: the FDA safety information and adverse event reporting program. Accessed June 17.2022https:\/\/www.fda.gov\/safety\/medwatch\u2010fda\u2010safety\u2010information\u2010and\u2010adverse\u2010event\u2010reporting\u2010program"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1809643"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocac153"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0709-4"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002763"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008915"},{"key":"e_1_2_10_11_1","unstructured":"Office of the Federal Register (OFR) of the National Archives and Records Administration (NARA) and the U.S. Government Publishing Office (GPO).FederalRegister.gov. Code of Federal Regulations. Title 21 Chapter II Part 1308 Schedules 1308.12 Schedule II. Accessed May 27.2022https:\/\/www.ecfr.gov\/current\/title-21\/chapter-II\/part-1308\/subject-group-ECFRf62f8e189108c4d\/section-1308.12"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T03:19:17Z","timestamp":1706066357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/pds.5661"],"URL":"https:\/\/doi.org\/10.1002\/pds.5661","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"2022-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}